{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:01:33Z","timestamp":1792119693792,"version":"4.4.0"},"reference-count":86,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T00:00:00Z","timestamp":1564876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010318","name":"Landelijke Stichting voor Blinden en Slechtzienden","doi-asserted-by":"publisher","award":["UitZicht 2018-3"],"award-info":[{"award-number":["UitZicht 2018-3"]}],"id":[{"id":"10.13039\/501100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010321","name":"Oogfonds","doi-asserted-by":"publisher","award":["2018-11"],"award-info":[{"award-number":["2018-11"]}],"id":[{"id":"10.13039\/501100010321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010302","name":"Algemene Nederlandse Vereniging ter voorkoming van Blindheid","doi-asserted-by":"publisher","award":["UitZicht 2018-3"],"award-info":[{"award-number":["UitZicht 2018-3"]}],"id":[{"id":"10.13039\/501100010302","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wealtheon","award":["x"],"award-info":[{"award-number":["x"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Germline pathogenic variants in the BRCA1-associated protein-1 (BAP1) gene cause the BAP1-tumor predisposition syndrome (BAP1-TPDS, OMIM 614327). BAP1-TPDS is associated with an increased risk of developing uveal melanoma (UM), cutaneous melanoma (CM), malignant mesothelioma (MMe), renal cell carcinoma (RCC), meningioma, cholangiocarcinoma, multiple non-melanoma skin cancers, and BAP1-inactivated nevi. Because of this increased risk, it is important to identify patients with BAP1-TPDS. The associated tumors are treated by different medical disciplines, emphasizing the need for generally applicable guidelines for initiating genetic analysis. In this study, we describe the path to identification of BAP1-TPDS in 21 probands found in the Netherlands and the family history at the time of presentation. We report two cases of de novo BAP1 germline mutations (2\/21, 9.5%). Findings of this study combined with previously published literature, led to a proposal of guidelines for genetic referral. We recommend genetic analysis in patients with \u22652 BAP1-TPDS-associated tumors in their medical history and\/or family history. We also propose to test germline BAP1 in patients diagnosed with UM &lt;40 years, CM &lt;18 years, MMe &lt;50 years, or RCC &lt;46 years. Furthermore, other candidate susceptibility genes for tumor types associated with BAP1-TPDS are discussed, which can be included in gene panels when testing patients.<\/jats:p>","DOI":"10.3390\/cancers11081114","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T03:25:22Z","timestamp":1564975522000},"page":"1114","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0660-6268","authenticated-orcid":false,"given":"Cindy","family":"Chau","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha M.","family":"van Poppelen","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands"},{"name":"Department of Ophthalmology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke","family":"van der Stoep","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3805-877X","authenticated-orcid":false,"given":"Arjen R.","family":"Mensenkamp","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf H.","family":"Sijmons","sequence":"additional","affiliation":[{"name":"Department of Genetics, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara W.","family":"van Paassen","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans M. W.","family":"van den Ouweland","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Naus","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke H.","family":"van der Hout","sequence":"additional","affiliation":[{"name":"Department of Genetics, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Potjer","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fonnet E.","family":"Bleeker","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke R.","family":"Wevers","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselotte P.","family":"van Hest","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn C. J.","family":"Jongmans","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands"},{"name":"Department of Clinical Genetics, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Marinkovic","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaco C.","family":"Bleeker","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2261-3820","authenticated-orcid":false,"given":"Martine J.","family":"Jager","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorius P. M.","family":"Luyten","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-1870","authenticated-orcid":false,"given":"Maartje","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,4]]},"reference":[{"key":"ref_1","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., and Amemiya, A. (1993). BAP1 Tumor Predisposition Syndrome. GeneReviews((R)), University of Washington. GeneReviews is a Registered Trademark of the University of Washington, Seattle. All Rights Reserved."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Pilarski","year":"2011","journal-title":"J. Med. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Njauw, C.N., Kim, I., Piris, A., Gabree, M., Taylor, M., Lane, A.M., DeAngelis, M.M., Gragoudas, E., Duncan, L.M., and Tsao, H. (2012). Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035295"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: Malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cancergen.2013.05.018","article-title":"Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma","volume":"206","author":"Cheung","year":"2013","journal-title":"Cancer Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1200\/JCO.2011.41.2965","article-title":"Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations","volume":"30","author":"Wiesner","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ajhg.2013.04.012","article-title":"Germline BAP1 mutations predispose to renal cell carcinomas","volume":"92","author":"Popova","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/1541-7786.MCR-13-0111","article-title":"A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma","volume":"11","author":"Farley","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/gcc.22129","article-title":"Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases","volume":"53","author":"Pilarski","year":"2014","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/neuonc\/nox094","article-title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/cge.12472","article-title":"Germline BAP1 mutations predispose also to multiple basal cell carcinomas","volume":"88","author":"Cabaret","year":"2015","journal-title":"Clin. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.pathol.2017.03.005","article-title":"Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma","volume":"49","author":"Rawson","year":"2017","journal-title":"Pathology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhang, A.J., Rush, P.S., Tsao, H., and Duncan, L.M. (2019). BRCA1-Associated Protein (BAP1) inactivated melanocytic tumors. J. Cutan. Pathol.","DOI":"10.1111\/cup.13530"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaad.2018.05.005","article-title":"Histomorphologic spectrum of germline-related and sporadic BAP1-inactivated melanocytic tumors","volume":"79","author":"Garfield","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00401-015-1423-2","article-title":"Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome","volume":"129","author":"Cabaret","year":"2015","journal-title":"Acta Neuropathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/pcmr.12006","article-title":"A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma","volume":"25","author":"Wadt","year":"2012","journal-title":"Pigment Cell Melanoma. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cge.12630","article-title":"Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases","volume":"89","author":"Rai","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_22","unstructured":"Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alf\u00f6ldi, J., Wang, Q., Collins, R.L., Laricchia, K.M., Ganna, A., and Birnbaum, D.P. (2019). Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamaophthalmol.2015.1119","article-title":"Clinical Characteristics of Uveal Melanoma in Patients with Germline BAP1 Mutations","volume":"133","author":"Gupta","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.ophtha.2016.01.008","article-title":"BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma","volume":"123","author":"Turunen","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/hmg\/ddz076","article-title":"Population-based analysis of BAP1 germline variations in patients with uveal melanoma","volume":"28","author":"Repo","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_26","first-page":"717","article-title":"A population-based analysis of germline BAP1 mutations in melanoma","volume":"26","author":"McLellan","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2014.10.017","article-title":"Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases","volume":"87","author":"Rusch","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/gcc.22218","article-title":"Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area","volume":"54","author":"Betti","year":"2015","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.gene.2015.03.031","article-title":"Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma","volume":"563","author":"Sneddon","year":"2015","journal-title":"Gene"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Panou, V., Gadiraju, M., Wolin, A., Weipert, C.M., Skarda, E., Husain, A.N., Patel, J.D., Rose, B., Zhang, S.R., and Weatherly, M. (2018). Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J. Clin. Oncol., Jco2018785204.","DOI":"10.1200\/JCO.2018.36.15_suppl.8564"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/ijc.31984","article-title":"Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A\/CDK4 melanoma families","volume":"144","author":"Potjer","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","article-title":"Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer","volume":"76","author":"Ohar","year":"2016","journal-title":"Cancer Res."},{"key":"ref_34","unstructured":"Mensenkamp, A.R., Sijmons, R.H., and van der Hout, A. Personal communication."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-61779-767-5_4","article-title":"Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders","volume":"867","author":"Vreeswijk","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cge.12501","article-title":"A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma","volume":"88","author":"Wadt","year":"2015","journal-title":"Clin. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.canlet.2016.05.011","article-title":"CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma","volume":"378","author":"Betti","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_39","unstructured":"Van Paassen, B.W. Personal communication."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/gcc.22473","article-title":"Occurrence of BAP1 germline mutations in cutaneous melanocytic tumors with loss of BAP1-expression: A pilot study","volume":"56","author":"Cabaret","year":"2017","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_41","unstructured":"Dutch National Cancer Registration 2013-2017, IKNL. Personal communication."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/bjc.2013.804","article-title":"Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma","volume":"110","author":"Dono","year":"2014","journal-title":"Br J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1167\/iovs.17-21838","article-title":"Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma","volume":"58","author":"Scholz","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ophtha.2017.12.022","article-title":"Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential","volume":"125","author":"Vaarwater","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_45","first-page":"5761","article-title":"Absence of BRAF and NRAS mutations in uveal melanoma","volume":"63","author":"Cruz","year":"2003","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.bjc.6602598","article-title":"Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS","volume":"92","author":"Zuidervaart","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/17469899.2014.921119","article-title":"Management of conjunctival malignant melanoma: A review and update","volume":"9","author":"Wong","year":"2014","journal-title":"Expert Rev. Ophthalmol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1167\/iovs.04-0344","article-title":"Conjunctival melanoma in the Netherlands: A nationwide study","volume":"46","author":"Missotten","year":"2005","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/aos.13007","article-title":"BRAF mutations in conjunctival melanoma: Investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions","volume":"94","author":"Larsen","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.canlet.2015.09.011","article-title":"Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction","volume":"369","author":"Cheung","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2486\/indhealth.45.379","article-title":"Malignant mesothelioma: Global incidence and relationship with asbestos","volume":"45","author":"Bianchi","year":"2007","journal-title":"Ind. Health"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2478\/raon-2018-0004","article-title":"The Influence of Genetic Variability on the Risk of Developing Malignant Mesothelioma","volume":"52","author":"Franko","year":"2018","journal-title":"Radiol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","article-title":"Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations","volume":"76","author":"Kadariya","year":"2016","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PAS.0b013e318263648c","article-title":"Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes","volume":"37","author":"Busam","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/cup.12493","article-title":"Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome","volume":"42","author":"Marusic","year":"2015","journal-title":"J. Cutan. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/PAT.0000000000000337","article-title":"BAP1 deficient malignant melanoma arising from the intradermal component of a congenital melanocytic naevus","volume":"47","author":"Ardakani","year":"2015","journal-title":"Pathology"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ward, W.H., and Farma, J.M. (2017). Epidemiology of Melanoma. Cutaneous Melanoma: Etiology and Therapy, Codon Publications.","DOI":"10.15586\/codon.cutaneousmelanoma.2017"},{"key":"ref_60","unstructured":"(2019, June 02). Erfelijk en Familair Melanoom. Available online: https:\/\/www.stoet.nl\/wp-content\/uploads\/2017\/04\/STOET-Richtlijnenboekje-april2017_DEF.pdf."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Pastorino, S., Yoshikawa, Y., Pass, H.I., Emi, M., Nasu, M., Pagano, I., Takinishi, Y., Yamamoto, R., Minaai, M., and Hashimoto-Tamaoki, T. (2018). A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations. J. Clin. Oncol., Jco2018790352.","DOI":"10.1200\/JCO.2018.79.0352"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","article-title":"Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Motzer","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1017\/thg.2015.12","article-title":"Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases","volume":"18","author":"Aoude","year":"2015","journal-title":"Twin Res. Hum. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2015.09.070","article-title":"Familial skin cancer syndromes: Increased melanoma risk","volume":"74","author":"Ransohoff","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamadermatol.2017.2330","article-title":"Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature","volume":"153","author":"Haugh","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ewens, K.G., Lalonde, E., Richards-Yutz, J., Shields, C.L., and Ganguly, A. (2018). Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5079-x"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/13816810.2015.1010734","article-title":"Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients","volume":"36","author":"Cebulla","year":"2015","journal-title":"Ophthalmic. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10689-010-9328-7","article-title":"Cancer family history characterization in an unselected cohort of 121 patients with uveal melanoma","volume":"9","author":"Pilarski","year":"2010","journal-title":"Fam. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/gcc.22424","article-title":"Germline BAP1 alterations in familial uveal melanoma","volume":"56","author":"Rai","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.22670","article-title":"Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes","volume":"57","author":"Betti","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Christensen, M.B., Wadt, K., Jensen, U.B., Lautrup, C.K., Bojesen, A., Krogh, L.N., Overeem Hansen, T.V., and Gerdes, A.M. (2019). Exploring the hereditary background of renal cancer in Denmark. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215725"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00008390-199506000-00005","article-title":"CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families","volume":"5","author":"Gruis","year":"1995","journal-title":"Melanoma. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2015-103150","article-title":"Melanoma genetics","volume":"53","author":"Read","year":"2016","journal-title":"J. Med. Genet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41467-018-04322-5","article-title":"Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors","volume":"9","author":"Rodrigues","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00251-019-01108-x","article-title":"Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab","volume":"71","author":"Johansson","year":"2019","journal-title":"Immunogenetics"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jfo.2015.04.003","article-title":"The genetic basis of uveal melanoma","volume":"38","author":"Nielsen","year":"2015","journal-title":"J. Fr. Ophtalmol."},{"key":"ref_77","unstructured":"(2019, June 02). Erfelijk en Familiar Niercelcarcinoom. Available online: https:\/\/www.stoet.nl\/wp-content\/uploads\/2017\/04\/STOET-Richtlijnenboekje-april2017_DEF.pdf."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaoncol.2018.1986","article-title":"Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma","volume":"4","author":"Carlo","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cancergen.2015.02.003","article-title":"Germline and somatic mutations in meningiomas","volume":"208","author":"Smith","year":"2015","journal-title":"Cancer Genet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jmg.2010.082420","article-title":"Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas","volume":"48","author":"Christiaans","year":"2011","journal-title":"J. Med. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/014556139907800208","article-title":"Neurofibromatosis type 2: Genetic and clinical features","volume":"78","author":"Evans","year":"1999","journal-title":"Ear. Nose Throat. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/02688690500081206","article-title":"Management of the patient and family with neurofibromatosis 2: A consensus conference statement","volume":"19","author":"Evans","year":"2005","journal-title":"Br J. Neurosurg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/neuonc\/nox228","article-title":"Germline SUFU mutation carriers and medulloblastoma: Clinical characteristics, cancer risk, and prognosis","volume":"20","author":"Dufour","year":"2018","journal-title":"Neuro. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"(1999). Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst., 91, 1310\u20131316.","DOI":"10.1093\/jnci\/91.15.1310"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.12.022","article-title":"Germline BAP1-positive patients: The dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy","volume":"92","author":"Star","year":"2018","journal-title":"Eur. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/8\/1114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:13:15Z","timestamp":1760188395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/8\/1114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,4]]},"references-count":86,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["cancers11081114"],"URL":"https:\/\/doi.org\/10.3390\/cancers11081114","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,4]]}}}